|
|
|
|
|
31.03.26 - 13:24
|
Teva receives FDA approval for Prolia biosimilar (PBR)
|
|
|
The FDA approval of Ponlimsi is based on a comprehensive evidence package, including analytical and clinical data showing immunogenicity, safety, and similar efficacy to Prolia. Ponlimsi is approved
The post Teva receives FDA approval for Prolia biosimilar appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.03.26 - 21:33
|
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 (GlobeNewswire EN)
|
|
|
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET....
|
|
|
19.03.26 - 21:33
|
Teva Releases Q1 2026 Aide Memoire (GlobeNewswire EN)
|
|
|
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website....
|
|
|
12.03.26 - 14:33
|
FUJIFILM Biotechnologies Appoints Christiane Bardroff as Chief Business Officer (Business Wire)
|
|
|
HILLERØD, Denmark--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced the appointment of Christiane Bardroff as Chief Business Officer (CBO), effective June 1, 2026. Bardroff will lead commercial and sales, business insights and intelligence, strategic partnerships and global marketing, reporting directly to President and CEO Lars Petersen.
Bardroff brings more than 18 years of experience and leadership across customer stewardship and biopharmaceutical operations, including process development and small-, mid-, and large-scale manufacturing, quality control, and quality assurance, as well as procurement, automation, and digitalization. Most recently, she was Chief Operating Officer at Rentschler Biopharma SE. Previously, she advanced through roles of increasing responsibility at Teva Biotech and Roche. As a people-first leader, she previously oversaw approximately 1,300 empl...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
